By Mill Chart
Last update: May 30, 2025
INCYTE CORP (NASDAQ:INCY) stands out as an intriguing candidate for value investors, according to our fundamental screening criteria. The biopharmaceutical company demonstrates a strong valuation profile while maintaining solid profitability and financial health. Below, we examine why INCY may be worth a closer look.
INCY scores an 8 out of 10 in valuation, indicating it is attractively priced relative to its fundamentals:
Despite a high trailing P/E (35.89), the forward earnings multiple suggests the market may be undervaluing INCY’s future earnings potential.
With a health rating of 7, INCY maintains a stable balance sheet:
INCY earns a profitability score of 7, supported by:
While growth is more moderate (rating of 4), there are positive signs:
Our Decent Value Stocks screener lists more stocks with similar characteristics. For a deeper dive, review the full fundamental report on INCY.
This is not investment advice. Always conduct your own research before making investment decisions.
65.06
-0.98 (-1.48%)
Find more stocks in the Stock Screener
INCYTE CORP (NASDAQ:INCY) presents a compelling value case with strong profitability, low debt, and an attractive valuation. The biotech firm's fundamentals suggest potential upside for long-term investors.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday.